Detection of subclinical coronary atherosclerosis using two-dimensional, high-resolution transthoracic echocardiography

Abstract

OBJECTIVESWe evaluated whether two-dimensional high-resolution transthoracic echocardiography (HR-2DTTE) can detect changes in arterial wall thickness and size associated with subclinical coronary artery disease (CAD).BACKGROUNDArterial wall thickening, compensatory arterial enlargement and a preserved arterial lumen characterize subclinical atherosclerosis. Detection of these changes during the asymptomatic stage of CAD may allow early treatment and prevention of acute coronary events.METHODSTwenty-six patients with angiographically proven CAD and 29 normal volunteers underwent HR-2DTTE evaluation of the left anterior descending coronary artery (LAD) using an ATL 5000 echograph (Advanced Technology Laboratories, Bothell, Washington) with a 4 to 7 MHz transducer. Significant (>70%) LAD stenosis was present in 15 patients (mean 82%); 11 patients did not have significant LAD stenosis (mean 26%) and represented a surrogate for subclinical LAD disease. Wall thickness, maximal luminal diameter and external diameter of the LAD were measured.RESULTSLeft anterior descending coronary artery wall thickness was larger in patients (1.9 ± 0.4 mm) than it was in volunteers (0.9 ± 0.1 mm, p < 0.001). The external diameter of the LAD was (6.0 ± 1.1 mm) in patients and (3.9 ± 0.7 mm) in volunteers (p < 0.001). Luminal diameter was 2.2 ± 0.5 mm in patients and 2.1 ± 0.6 mm in volunteers (p = NS). There was no difference in wall thickness (1.9 ± 0.4 mm vs. 2.0 ± 0.4 mm), luminal diameter (2.2 ± 0.5 mm vs. 2.2 ± 0.4 mm) and external diameter (5.9 ± 1.0 mm vs. 6.2 ± 1.2 mm) between the patients with <70% and >70% LAD stenosis.CONCLUSIONSLeft anterior descending coronary artery wall thickness and external diameter are significantly increased in patients with CAD as compared with normal subjects, and HR-2DTTE is sensitive enough to detect these differences. Wall thickness and external diameter are increased to the same extent in patients with obstructive and subclinical LAD disease.